Loading
institutionsInstitution
Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH
Austria's leading academic cancer centre at the Vienna General Hospital, known for the ABCSG breast trials, brain metastasis research and the MedAustron ion therapy centre.
Also called: CCC ViennaMedUni WienAllgemeines Krankenhaus Wien
Overview
The Comprehensive Cancer Center Vienna joins the Medical University of Vienna and the Vienna General Hospital (AKH), one of Europe's largest hospitals. Michael Gnant's Austrian Breast and Colorectal Cancer Study Group ran the ABCSG-12 and ABCSG-18 trials that defined adjuvant bone-targeted therapy and co-led the PALLAS trial of adjuvant palbociclib, Matthias Preusser's neuro-oncology group is a European reference for brain metastases and glioma trials, and Ulrich Jäger's haematology division leads lymphoma and CAR-T programmes. The university's radiation oncology department under Dietmar Georg provides the clinical programme at MedAustron in Wiener Neustadt, Austria's proton and carbon-ion therapy centre. The CCC also hosts the Institute of Cancer Research and a large phase 1 unit.
Location
Vienna, AT
Type
cancer center · Medizinische Universität Wien
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#176 · 30 points (0 Newsweek + 0 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Medical University of Vienna, including child institutions. 1,369 works · 18,391 citations · 77% open access · 9% clinical trials · 3% reviews.
Oncology works per year
2892022
3132023
2962024
2742025
1972026
Most works
- Gerald W. Prager76 works
- Oliver Strobel66 works
- Harald Kittler65 works
- Matthias Preusser55 works
- Philipp Tschandl52 works
- Michael A Trauner45 works
- Rupert Bartsch43 works
- Marcus Hacker39 works
- Carl-Stephan Leonhardt39 works
- Monika Ferlitsch36 works
Most cited
- Austrian Breast and Colorectal Cancer Study Group
- Brain metastases and neuro-oncology
- MedAustron proton and carbon-ion therapy
- Haematology and CAR-T
- Phase 1 unit
Gerald W. Prager
Gastrointestinal medical oncologist, Medical University of Vienna
Colorectal cancerAnti-angiogenic therapyLater-line chemotherapy
Vienna oncologist who was lead author of SUNLIGHT, the trial that showed adding bevacizumab to trifluridine-tipiracil lengthens survival in refractory colorectal cancer.
Nicole Concin
Coordinator, Gynecologic Cancer Unit; Head, Department of Obstetrics and Gynecology
Gynaecologic oncologyEndometrial cancerOvarian cancer
Gynaecologic oncologist who leads Vienna's women's clinic and is first author of the ESGO/ESTRO/ESP endometrial cancer guidelines.
Rupert Bartsch
Medical oncologist, Medical University of Vienna
Breast cancer brain metastasesHER2-positive breast cancerAntibody-drug conjugates
Vienna oncologist who led TUXEDO-1, the small trial that showed trastuzumab deruxtecan can shrink active brain metastases from HER2-positive breast cancer.
Shahrokh F. Shariat
Head of the Comprehensive Cancer Center Vienna; Head, Department of Urology
Urologic oncologyBladder cancerProstate cancer
Prolific urologic oncologist who chairs Vienna's Department of Urology and leads the Comprehensive Cancer Center of MedUni Wien and AKH.
Similar pages
- CompanyAustrian Breast & Colorectal Cancer Study Group
Shares Breast International Group (BIG), Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs).
- InstitutionEdinburgh Cancer Centre / CRUK Scotland Centre
Shares Breast International Group (BIG), CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Glioma & glioblastoma.
- TrialA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- CompanyGEICAM Spanish Breast Cancer Group
Shares Breast International Group (BIG), Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs).
- PairingCDK4/6 inhibitor + endocrine therapy
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs).
- InstitutionCleveland Clinic Abu Dhabi
Shares Proton therapy, CAR-T cell therapy, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer.
- TrialpersevERA
Shares Palbociclib, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
cancers
fronts
technologies
drugs
ApprovedSmall-molecule CDK4/6 inhibitor
Palbociclib · Ibrance